When I google “autism” and “PAK1”, I keep seeing my own posts come up. This is beginning to be a regular occurrence, when I research an idea. Google “verapamil autism”, “clonazepam autism” “bumetanide autism” and even “NAC autism”, the same thing happens.
So it is nice to have some further studies that also show the possible importance of PAK1 in treating autism. This time it is from the University of Indiana and more precisely, Anantha Shekhar, Professor of Psychiatry at the School of Medicine.
We have the study’s abstract and the more people-friendly press release.
Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase (PAK1)
Children with neurofibromatosis type 1 (NF1) are increasingly recognized as having a high prevalence of social difficulties and autism spectrum disorders (ASDs). We demonstrated a selective social learning deficit in mice with deletion of a single Nf1 allele (Nf1+/−), along with greater activation of the mitogen-activated protein kinase pathway in neurons from the amygdala and frontal cortex, structures that are relevant to social behaviors. The Nf1+/− mice showed aberrant amygdala glutamate and GABA neurotransmission, deficits in long-term potentiation and specific disruptions in the expression of two proteins that are associated with glutamate and GABA neurotransmission: a disintegrin and metalloprotease domain 22 (Adam22) and heat shock protein 70 (Hsp70), respectively. All of these amygdala disruptions were normalized by the additional deletion of the p21 protein-activated kinase (Pak1) gene. We also rescued the social behavior deficits in Nf1+/− mice with pharmacological blockade of Pak1 directly in the amygdala. These findings provide insights and therapeutic targets for patients with NF1 and ASDs.
Here is the very informative and readable press release.
INDIANAPOLIS -- Blocking a single gene that is active in the brain could provide a means to lessen behavioral problems among children with a common genetic disease, many of whom are also diagnosed with an autism disorder, according to researchers at the Indiana University School of Medicine.
The genetic disorder, neurofibromatosis type 1, is one of the most common single-gene diseases, affecting about 1 in 3,000 children worldwide. Symptoms can range from café-au-lait spots on the skin to tumors that are disfiguring or that can press dangerously against internal organs.
"Physicians are increasingly recognizing that many children with the disorder have social and behavioral difficulties, and as many as one in five cases of autism may be associated with the same biochemical defects seen in neurofibromatosis type 1," said Anantha Shekhar, M.D., Ph.D., Raymond E. Houk Professor of Psychiatry at the IU School of Medicine.
The researchers used a mouse model of neurofibromatosis, examining both behavioral differences from normal mice and biochemical differences in the animals' brains, particularly in the amygdala, a brain structure associated with social behavior and emotional regulation.
Reporting their work in the journal Nature Neuroscience, the researchers found that the neurofibromatosis model mice had problems with long term social learning -- remembering important social cues involving interactions with other mice. Tests also showed that neurochemical pathways between structures of the brain involved with social behavior were disrupted by the neurofibromatosis mutation.
However, blocking the activity of another gene -- called Pak1, which is involved with those neurochemical pathways -- improved the social behaviors of the mice. Mice bred to have both the neurofibromatosis mutation and the deletion of the Pak1 gene engaged in social behavior similar to normal mice. In addition, mice with the neurofibromatosis mutation that were injected with a compound known to block Pak1 gene activity had normal social behavior restored.
"These findings could lead to novel approaches to treating behavioral problems that are seen in NF1 patients and some patients with autism spectrum disorders," said D. Wade Clapp, M.D., Richard L. Schreiner Professor of Pediatrics at the IU School of Medicine.
The researchers from Indiana are suggesting that 20% of people with autism may have the same dysfunction as the very much rarer condition of neurofibromatosis type 1. Those 20% are likely to benefit from treatments shown to be effective in NF-1.
How do you know whether you are in the 20%? A little genetic testing might tell you, or maybe not (see below).
In the absence of such testing, you could possibly deduce something from looking at the comorbidities.
It might seem odd that NF-1, a rare disorder affecting 1 in 3,000 children could share its underpinnings with 20% of children with autism, which would roughly equate to 6 in 3,000 children.
This reminds me of a question I raised earlier:-
In that post it became clear that you can have a partial dysfunction of a “rare” genetic disorder. I wonder if that partial dysfunction will show up on today’s genetic tests.
The comorbidities of autism that most intrigue me are asthma, allergies and ulcerative colitis. I have a suspicion that they are all linked by mast cell degranulation and further, that what is underlying autism is promoting mast cells to degranulate.
A recent study showed how PAK1 is involved in modulating mast cell degranulation:-
And another one:-
Fortunately, the effects of PAK1-deficiency on the immune system have a very encouraging up-side. As demonstrated by otherwise relatively healthy PAK1-/- mice, Pak1 is critical for disassembly of cortical F-actin upon allergen stimulation, and PAK1 deficiency prevents the release of pro-inflammatory molecules from the granules of mast cells during the IgE-associated allergic responses
I have already shown the effectiveness of Verapamil as a therapy for autism and mast cell degranulation. I suspect that a further improvement may follow with a potent PAK1 inhibitor.
I think the Indiana research also points in the same direction.
There is also the issue of malformed dendritic spines, which will be fully addressed in a later post. This appears in autism and schizophrenia and may explain much of why autistic brains function differently to other peoples. It is thought that this malformation is also linked to PAK1.
So while treating mast cell degranulation will help some people’s autism, you could also go one step backwards up the chain and address the signal that was prompting them to degranulate. This same signal may trigger an unrelated damaging cascade of events elsewhere in the brain.
Which PAK1 inhibitor?
In earlier post we saw that the choices of PAK1 inhibitor are:-
1. Experimental drugs still under development by Afraxis, the MIT spin-off
2. Ivermectin, an old anti-parasite drug, used with some success by fringe alternative doctors in the US. At least one reader of this blog is a fan of Ivermectin for autism.
3. Certain types of Propolis, like the one containing CAPE (Caffeic Acid Phenethyl Ester) that comes from New Zealand
The question remains whether the Propolis is potent enough to have the same effect as Ivermectin. In the NF-1 and NF-2 community, opinion is split as to whether Propolis can shrink existing tumours. This issue of stopping new tumours developing, versus shrinking existing ones does seem to crop up quite often in cancer research as well. Drugs are, not surprisingly, most effective when used very early on.
Ivermectin cannot be used long term continuously, since it is toxic. It can be used “on and off” for decades as an anti-parasite therapy.
Crossing the Blood Brain Barrier
Once question arose in an earlier post as to how Ivermectin could be effective in autism, since it does not readily cross the blood brain barrier. According to the experts it does not have to, see below:-
11. Expert opinion: Is PAK1 a suitable target for therapy?
As discussed above, there is growing evidence that PAKs are involved in the phenomena that are clinically significant for various cardio-vascular disorders, but the specificity of PAK1 involvement is still uncertain. Studies indicate that even closely related PAKs (e.g. PAK1 and PAK2) have non-identical sets of substrates. The issue is further complicated because of the multiple and sometimes opposing roles of PAKs in these processes and certainly merits further investigation.
The reports on the involvement of PAK1 in various diseases of the brain indicate that both up- and down-regulation of this enzyme may be associated with pathological changes. This, along with the uncertainty about the relative contribution of other isoforms, clouds the prospect of targeting PAK1 for therapeutic intervention in these conditions. Furthermore, these observations necessitate a close attention to the affects that any anti-PAK therapy targeted at other organs might have on the nervous system, including the cognitive functions and the memory. In this regard, failure of an anti-PAK1 agent to penetrate the blood-brain barrier may not be a detriment to its therapeutic utility. Similarly complicated is the question of PAK1 targeting in infections: while it may partially attenuate certain viruses, it would also negatively impact some functions of the immune system. In fact, the recent report of PAK1-deficient animals having IgE-mediated responses to allergens may indicate that, at least, for such acute life-threatening conditions as anaphylaxis the benefits of suppressing PAK1 may outweigh the risks.
My PAK-1 inhibitor Trial
I am practicing what I preach, so to speak. Only once the pollen allergy season is well and truly over, will I trial my PAK-1 inhibitor. I want a genuine result, free from external effects, like degranulating mast cells.
Since Ivermectin is known to react with other drugs in my PolyPill, I will be using the Propolis from New Zealand.